https://www.selleckchem.com/pr....oducts/bms-935177.ht
OBJECTIVES Biologic disease-modifying antirheumatic drugs (bDMARDs) are prescribed sequentially in the treatment of rheumatoid arthritis (RA). Healthcare decision makers continue to debate their use, mainly because of their high costs. Our aim was to perform an economic evaluation for France of bDMARD sequences for treatment of moderate-to-severe RA after inadequate response or intolerance to conventional DMARDs (eg, methotrexate). METHODS A discretely integrated condition event simulation was developed to track the course of patient
Like
Comment
Share
